Skip to content

ImmunityBio, Inc. IBRX Class of Warrant or Right, Outstanding

Class of Warrant or Right, Outstanding at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s class of warrant or right, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s class of warrant or right, outstanding?
ImmunityBio, Inc. (IBRX) reported class of warrant or right, outstanding of $47.86M in Q1 2026.
How has ImmunityBio, Inc.'s class of warrant or right, outstanding changed year-over-year?
ImmunityBio, Inc.'s class of warrant or right, outstanding increased by 647.9% year-over-year, from $6.4M to $47.86M.
What is the long-term trend for ImmunityBio, Inc.'s class of warrant or right, outstanding?
Over 2 years (2023 to 2025), ImmunityBio, Inc.'s class of warrant or right, outstanding has grown at a 31.3% compound annual growth rate (CAGR), from $37.73M to $65.05M.